Press Release Archives - Page 8 of 23

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Baxter to act as exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA TORONTO, Canada – February 21, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for...

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

TORONTO, Canada – February 15, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment...

Spectral Medical Provides Early February Tigris Trial Update

88 patients enrolled January being the highest enrollment month since the launch of Tigris TORONTO, Canada – February 5, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options...

Spectral Medical Provides January Tigris Trial Update

85 Patients Enrolled TORONTO, Canada – January 30, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris...

Spectral Medical Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

New patient enrollment sites accelerating screening activity Screening activity exceeding 100 patients per week Approaching interim enrollment target of 90 patients TORONTO, Canada – January 10, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...

Spectral Medical Provides Tigris Trial Update

81 patients enrolled TORONTO, Canada – December 14, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.